IL117116A0 - A medical composition for the in vivo transfection and expression of exogenes - Google Patents

A medical composition for the in vivo transfection and expression of exogenes

Info

Publication number
IL117116A0
IL117116A0 IL11711696A IL11711696A IL117116A0 IL 117116 A0 IL117116 A0 IL 117116A0 IL 11711696 A IL11711696 A IL 11711696A IL 11711696 A IL11711696 A IL 11711696A IL 117116 A0 IL117116 A0 IL 117116A0
Authority
IL
Israel
Prior art keywords
exogenes
expression
medical composition
vivo transfection
vivo
Prior art date
Application number
IL11711696A
Other languages
English (en)
Original Assignee
Inst Nat Sante Rech Med
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Rhone Poulenc Rorer Sa filed Critical Inst Nat Sante Rech Med
Publication of IL117116A0 publication Critical patent/IL117116A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
IL11711696A 1995-02-14 1996-02-12 A medical composition for the in vivo transfection and expression of exogenes IL117116A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9501662A FR2730411B1 (fr) 1995-02-14 1995-02-14 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes

Publications (1)

Publication Number Publication Date
IL117116A0 true IL117116A0 (en) 1996-06-18

Family

ID=9476106

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11711696A IL117116A0 (en) 1995-02-14 1996-02-12 A medical composition for the in vivo transfection and expression of exogenes

Country Status (23)

Country Link
US (2) US20030004091A1 (xx)
EP (1) EP0809516B1 (xx)
JP (1) JPH11500430A (xx)
KR (1) KR100402540B1 (xx)
AT (1) ATE204481T1 (xx)
AU (1) AU717218B2 (xx)
BR (1) BR9607310A (xx)
CA (1) CA2211039C (xx)
CZ (1) CZ258197A3 (xx)
DE (1) DE69614668T2 (xx)
DK (1) DK0809516T3 (xx)
ES (1) ES2163612T3 (xx)
FI (1) FI119176B (xx)
FR (1) FR2730411B1 (xx)
GR (1) GR3036438T3 (xx)
HU (1) HU222991B1 (xx)
IL (1) IL117116A0 (xx)
MX (1) MX9706017A (xx)
NO (1) NO320072B1 (xx)
PT (1) PT809516E (xx)
SK (1) SK282235B6 (xx)
WO (1) WO1996025177A1 (xx)
ZA (1) ZA961161B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
WO1998008539A1 (en) * 1996-08-26 1998-03-05 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
AU1288099A (en) 1997-10-30 1999-05-24 Cornell Research Foundation Inc. A method of inhibiting an immune response to a recombinant vector
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
WO2000074688A1 (en) * 1999-06-08 2000-12-14 The Children's Hospital Of Philadelphia Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
CN100494182C (zh) * 2000-05-12 2009-06-03 基酶有限公司 肿瘤坏死α因子信号的调节因子
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
US20030211075A1 (en) * 2001-09-27 2003-11-13 Thorpe Philip E. Combined compositions for tumor vasculature coagulation and treatment
ES2371635T3 (es) * 2002-11-21 2012-01-05 Genzyme Corporation Combinación de un derivado de diamida y agentes inmunosupresores para inhibir el rechazo de transplantes.
ATE493980T1 (de) * 2002-11-21 2011-01-15 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
JP2007520566A (ja) * 2004-02-04 2007-07-26 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 自己免疫治療のための抗cd3及び抗原特異的免疫療法
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
WO1994016080A1 (en) * 1993-01-08 1994-07-21 Exemplar Corporation An in vitro/in vivo method for identifying anti-neoplastic drugs
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus

Also Published As

Publication number Publication date
FI973323A (fi) 1997-08-13
CA2211039C (fr) 2011-12-06
ES2163612T3 (es) 2002-02-01
ATE204481T1 (de) 2001-09-15
NO973724D0 (no) 1997-08-13
HU222991B1 (hu) 2004-01-28
SK282235B6 (sk) 2001-12-03
AU717218B2 (en) 2000-03-23
JPH11500430A (ja) 1999-01-12
DK0809516T3 (da) 2001-12-17
FR2730411B1 (fr) 1997-03-28
BR9607310A (pt) 1997-11-25
SK110897A3 (en) 1998-01-14
FR2730411A1 (fr) 1996-08-14
EP0809516B1 (fr) 2001-08-22
KR19980702199A (ko) 1998-07-15
US20030004091A1 (en) 2003-01-02
NO320072B1 (no) 2005-10-17
FI119176B (fi) 2008-08-29
AU4723896A (en) 1996-09-04
HUP9800635A2 (hu) 1998-07-28
KR100402540B1 (ko) 2004-05-07
NO973724L (no) 1997-08-13
MX9706017A (es) 1997-11-29
PT809516E (pt) 2002-02-28
CA2211039A1 (fr) 1996-08-22
FI973323A0 (fi) 1997-08-13
ZA961161B (en) 1996-08-07
HUP9800635A3 (en) 2000-12-28
CZ258197A3 (en) 1997-11-12
DE69614668T2 (de) 2002-06-27
US20040265276A1 (en) 2004-12-30
DE69614668D1 (de) 2001-09-27
EP0809516A1 (fr) 1997-12-03
WO1996025177A1 (fr) 1996-08-22
GR3036438T3 (en) 2001-11-30

Similar Documents

Publication Publication Date Title
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
IL117116A0 (en) A medical composition for the in vivo transfection and expression of exogenes
GR3032744T3 (en) Surface expression of enzyme in gene directed prodrug therapy
MX9706109A (es) Moleculas de adn, preparacion y utilizacion en terapia genica.
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
CY2396B1 (en) Pharmaceutical composition of fenofibrate with high biological availability and method for preparingsame.
NZ335799A (en) Improvements in or relating to diagnostic/therapeutic agents
BG102022A (en) Metering inhaler for salmetrol
DE69835201D1 (en) Neoglycoproteine
AU5788096A (en) Plasmid for delivery of nucleic acids to cells and methods of use
EP0766974A3 (en) Blood reservoir, blood delivery instrument, and blood delivery apparatus
MX9801264A (es) Control de la expresion del gen de cd44 para uso terapeutico.
MX9606327A (es) Adenovirus que comprende un gen que codifica para un superoxido dismutasa.
HUP9900317A3 (en) Pharmaceutical composition useful for nucleic acid transfection, and use thereof
AU3698297A (en) Compositions containing at least one nucleic acid and their applications in the biomedical field, particularly in gene therapy
MX9700298A (es) Adenovirus que comprende un gen que codifica para una no sintasa.
HUP9904201A3 (en) Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent
AU2001258638A1 (en) Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.
AU2298195A (en) An (in vivo) gene expression system
ITRM940545A0 (it) Preparato ad uso cosmetico e/o farmaceutico, con carbone attivo e sostanze disperdenti.